CP and colitis: Treatment with the control TLR-i peptide lacking the cell-penetrating conjugate or the CP peptide alone did not affect the colitis symptoms, which include body weight loss, diarrhea, rectal bleeding, and reduced colon length (Supplementary Figure S2).